Detalhe da pesquisa
1.
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Blood
; 143(14): 1399-1413, 2024 Apr 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38194688
2.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38012435
3.
Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw.
Int J Mol Sci
; 25(3)2024 Jan 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38338876
4.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37354090
5.
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Am J Hematol
; 98(11): 1762-1771, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37647134
6.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34636033
7.
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood
; 135(8): 534-541, 2020 02 20.
Artigo
Inglês
| MEDLINE | ID: mdl-31877211
8.
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
Haematologica
; 107(10): 2356-2364, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35385922
9.
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol
; 193(2): 271-279, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33403687
10.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33388860
11.
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Acta Oncol
; 60(11): 1527-1533, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34499575
12.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-32474619
13.
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Haematologica
; 104(8): 1589-1596, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30819917
14.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol
; 37(3): 296-302, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-30892724
15.
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Ann Hematol
; 98(10): 2329-2338, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-31392461
16.
Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report.
Acta Haematol
; 141(4): 261-267, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30965317
17.
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias.
Int J Mol Sci
; 20(24)2019 Dec 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31817063
18.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Int J Mol Sci
; 20(9)2019 May 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31064152
19.
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.
J Cell Mol Med
; 22(2): 1070-1080, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29218828
20.
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.
Mol Cancer
; 17(1): 56, 2018 02 19.
Artigo
Inglês
| MEDLINE | ID: mdl-29455672